USFDA issues EIR for Alembics Panelav oncology injectable formulation unit

  • capital market |
  • 09 Dec, 2022 |
  • 1:39 PM
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at the companys Oncology Injectable Formulation Facility at Panelav during the period from 4 October 2022 to 14 October 2022. This was pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA. The Company had also started receiving ANDA approval manufactured at this facility.Powered by Capital Market - Live News

Invest wise with Expert advice

ad IconAd Image

Most Read News

Article Image
  • 14 March, 2022 |
  • 7:03 AM

The US Federal committee's meeting will conclude on March 16, 2022.

Most Shared News

No Record Found